Bend Research Inc.

North Bend, OR, United States

Bend Research Inc.

North Bend, OR, United States

Time filter

Source Type

Patent
Bend Research Inc., Medivation Prostate Therapeutics Inc. and Astellas Pharma Inc. | Date: 2016-02-08

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.


Patent
Bend Research Inc. | Date: 2016-11-18

A sample can be collected from an enclosed container by opening a sample collection valve and drawing the sample from the enclosed container. After delivery of the sample out of a fluid flow path, a sanitizing fluid can be directed along the fluid flow path to sanitize the fluid flow path.


Patent
Bend Research Inc. | Date: 2017-02-15

The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality of particles, and collecting the particles. The spray solution may be formed by forming a feed suspension comprising the active agent, the matrix material, and the organic solvent, wherein the feed suspension is at a temperature T_(1), and directing the feed suspension to a heat exchanger, thereby increasing the temperature of the feed suspension to a temperature T_(2), wherein T_(2) is greater than T_(1), and the spray solution is at a pressure greater than the vapor pressure of the organic solvent at T_(2), such that the active agent and matrix material are soluble in the organic solvent at T_(2).


Patent
Bend Research Inc. | Date: 2017-05-31

Disclosed are compositions including nanoparticles comprising a poorly aqueous soluble polymer, an ionizable active agent, and a counterion having an opposite charge as the ionizable active agent, as well as methods of making and using the compositions.


Patent
Bend Research Inc., Medivation Prostate Therapeutics Inc. and Astellas Pharma Inc. | Date: 2016-09-16

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.


A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.


Patent
Bend Research Inc. | Date: 2015-06-12

A spray-drying apparatus includes a drying chamber that has a first end, a second end, and at least one side wall extending between the first and second ends to define an interior of the drying chamber having a center axis. A nozzle can be positioned at the first end of the drying chamber and be configured to atomize liquid and spray the atomized liquid into the interior of the drying chamber at a maximum spray pattern angle relative to the center axis. A heating device can be provided to heat the liquid prior to introduction into the drying chamber.


In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.


Patent
Bend Research Inc. | Date: 2015-02-09

A spray-drying apparatus includes a drying chamber that has a first end, a second end, and at least one side wall extending between the first and second ends to define an interior of the drying chamber having a center axis. A nozzle can be positioned at the first end of the drying chamber and be configured to atomize liquid and spray the atomized liquid into the interior of the drying chamber at a maximum spray pattern angle relative to the center axis. A ratio of the length between the first end and second end to a maximum width between opposing internal surfaces of the interior of the drying chamber can be at least 5 to 1.


Patent
Bend Research Inc. | Date: 2015-03-16

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Loading Bend Research Inc. collaborators
Loading Bend Research Inc. collaborators